Insights - Affimed & MD Anderson reported an update on their AFM13+NK cell program. The data was very promising and exceeded expectations with continued dose response and durability. The Data … Continue Reading
Premium: Read NowInsights - Big news this week in bio land is that Nektar/Bristol Myers IL-2 drug failed to benefit patients with melanoma. The primary endpoints of overall survival (OS) and … Continue Reading
Premium: Read NowInsights - Yesterday, Medicenna (MDNA) announced a clinical advisory board and strategic advisors. In the end of the press release, MDNA disclosed that Chief Scientific Officer Dr. Kevin Moulder … Continue Reading
Premium: Read NowInsights - 9 Meters Bio (NMTR) shared yesterday that their topline results for Phase 2 in Short Bowel Syndrome (SBS) will be pushed back to Q2 2022. … Continue Reading
Premium: Read NowInsights - The XBI biotech index was starting a see some consolidation during February in the low-mid $90s. However, that was interrupted by the ongoing tensions between … Continue Reading
Premium: Read NowInsights - Last week, general and biotech-specific markets were attentive to macroeconomics & the FED’s plans to raise rates to fight rising inflation. The monetary tightening is … Continue Reading
Premium: Read NowInsights - The XBI has fallen below the $100 range, down 40% from peak a year ago. The largest healthcare conference (JP Morgan 2022), which took place … Continue Reading
Premium: Read Now
